Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
EZH2 (the Enhancer of Zeste Homolog 2), as a key epigenetic regulator and
EMT
inducer, participates in a variety of cancer metastasis. EZH2 stability is regulated by several types of post-translational modifications (PTMs).The long non-coding RNAs (lncRNA) have been implicated to have critical roles in multiple carcinogenesis through a wide range of mechanisms, including modulating the stability of proteins. To date, whether the stability of EZH2 protein is regulated by lncRNAs remains unexplored. Here we report the discovery of
ANCR
modulating the stability of EZH2, and hence in the invasion and metastasis of breast cancer cells. We determined that
ANCR
potentiated the CDK1-EZH2 interaction, which then increased the intensity of phosphorylation at Thr-345 and Thr-487 sites of EZH2, facilitating EZH2 ubiquitination and hence its degradation. Moreover, we also uncover
ANCR
is an important player in breast cancer progression and metastasis mainly through decreasing EZH2 stability. More specifically, we initially found that
ANCR
level was lower in breast cancer tissues and breast cancer cell lines, in contrast to their normal counterparts. We then demonstrated that knockdown of
ANCR
induced an
EMT
program and promoted cell migration and invasion in MCF10A (epithelial cells), whereas ectopic expression of
ANCR
repressed breast cancer cells migration and invasion. Furthermore, we validated in a nude mouse model that overexpression of
ANCR
in highly malignant and invasive MDA-MB-231 breast cancer cells significantly reduced the ability of the cells to form tumors and prevented the lung metastasis in vivo. Based on these data, our findings define a new mechanism underlying modulation of EZH2 stability by linking
ANCR
interaction with EZH2 to promote its phosphorylation that facilitates EZH2 degradation and suppresses breast cancer progression.
...
PMID:The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. 2771 45